Category Archives: Institutional and special event

2018 Ebola Epidemics: What is the Latest in Vaccine Research?

Since July, a new outbreak of Ebola virus disease was identified in the Democratic Republic of the Congo – the second since May. In an attempt to halt the outbreak, a new vaccination campaign has begun in the affected region of North Kivu. It is against this background that researchers from the consortium PREVAC (Partnership for Research on Ebola VACcination) take stock of advances in Ebola vaccine research in The Lancet and point to the necessity to continue clinical trials.

A Summer of Science and Art with the Participation of Inserm

Inserm has long played a proactive role in scientific outreach in order to share science and biomedical research advances with the general public. And this summer 2018 will be no exception, with its host of events in which art and science will meet, in which our researchers will participate in La recherche de l’art #7 in Arles, Binôme in Avignon, and the Science in The City festival in Toulouse. The diary of Inserm’s scientific and cultural events, which include a photography exhibition, play, and visual performances, is presented below.

Le Professeur Christine Petit reçoit le Prix Kavli 2018

L’Institut Pasteur, le Collège de France, l’Académie des sciences et l’Inserm sont honorés d’annoncer la décision de l’Académie norvégienne des sciences et des lettres de remettre le Prix Kavli 2018 en neurosciences à Christine Petit pour son travail pionnier sur les mécanismes moléculaires et neuronaux de l’audition. Cette récompense, décernée tous les deux ans, consiste en un fonds d’un million de dollars (US) qui sera partagé entre Christine Petit et deux autres chercheurs de renommée internationale : A. James Hudspeth (Université Rockfeller, États-Unis) et Robert Fettiplace (Université du Wisconsin, États-Unis). La cérémonie de remise du prix se tiendra à Oslo le 4 septembre 2018.

May ’68, Lived and Recounted by the French Scientific Community

Mai 1968 a mis la société française en ébullition. La communauté scientifique ne fait pas exception à la règle, cette dernière s’est mise à protester et à réinventer le monde de la science : les universités ont été bloquées, les hôpitaux se sont mis en grève et dans les laboratoires de recherche les vieilles pratiques ont été dénoncées. Découvrez “Mai 68, la science s’affiche”, une série de courts-métrages qui revient sur les évènements qui ont révolutionné le monde universitaire et hospitalier. Une série créée avec le soutien de l’Inserm, en coproduction avec CNRS Images et Schuch productions, en association avec Universcience et avec la participation du Centre national du cinéma et de l’image animée.

Achievements in Innovation: Inserm Sets Itself Apart Once Again Through its Momentum and Results

The respective classifications of the European Patent Office (EPO) and France’s National Industrial Property Institute (INPI), which have just published their annual rankings for 2017, have confirmed Inserm’s ability to innovate. Inserm placed first among patent applicants in the pharmaceutical sector for the second year in a row, yet again leading the rankings of European applicants in this sector, ahead of both industrial manufacturers and academic institutions. Furthermore, the Institute was in 30th place – having moved up five places – in the INPI’s “patents in all fields” ranking, confirming its research teams’ excellence and productivity in innovation.

Artificial Intelligence to serve health research: Inserm and Owkin join forces

Accelerate artificial intelligence research to benefit health: such is the shared objective underpinning the agreement signed by Inserm and the start-up Owkin, specialized in machine learning applied to biological and medical research. The tools developed by Owkin, combined with the mass of health data either produced or used by Inserm, will lead to the development of disruptive innovations unprecedented in the field of medical and clinical research.

UK-France Summit. United Kingdom of Great Britain and Northern Ireland. Genomic Medicine, the Focus of the Agreement Supported by Aviesan

To become the most advanced and competitive genomics research and healthcare system in the world: such was the ambition declared by Inserm, and its partners Aviesan and Genomics England Ltd, during the UK-France Summit on January 18, 2018. An agreement was signed by Sir John Chisholm, Executive Chairman of Genomics England Ltd, and Yves Levy, Chairman and Chief Executive Officer of Inserm, and Chairman of Aviesan, which heads up the governmental “French Plan for Genomic Medicine 2025”. They signed it in the presence of the President of the French Republic, Emmanuel Macron, and UK Prime Minister, Theresa May.

What does science say about the eleven vaccines that will be mandatory for all children in France starting in 2018? INSERM has just published an official report.

In the context of the extension of mandatory vaccination that will go into effect in 2018, immunization is becoming a topic of public debate. People are often ill-informed, basing their opinions on the catastrophist arguments of anti-vaccine lobbies and the lack of relevant training on the part of medical professionals. France has become one of the countries where defiance against vaccination is at its strongest worldwide. The controversy is happening despite the facts that the mandatory vaccinations match the current immunization calendar and that no additional vaccines have been added. The purpose of this measure is to ensure that children are actually receiving the vaccines that are scheduled for all children.

Claire Giry becomes Deputy Director General of Inserm

She replaces Thierry Damerval, who has been appointed Chairman and CEO of the French National Research Agency (ANR).

Thierry Damerval is moving on to a new role after 10 years with Inserm’s Directorate General.

Thierry Damerval was appointed President and CEO of the French National Research Agency (ANR) by presidential decree on December 8, 2017, having been proposed for the role by the Minister for Higher Education, Research and Innovation.

fermer
fermer
RSS Youtube